Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: in vitro and in vivo studies in acute leukemia

Oncogene volume 25, pages 5719–5725 (2006)Cite this article

Abstract

The telomerase complex is responsible for telomere maintenance and represents a promising neoplasia therapeutic target. Recently, we have demonstrated that treatment with a G-quadruplex-interactive agent, telomestatin reproducibly inhibited telomerase activity in the BCR-ABL-positive leukemic cell lines. In the present study, we investigated the mechanisms of apoptosis induced by telomerase inhibition in acute leukemia. We have found the activation of caspase-3 and poly-(ADP-ribose) polymerase in telomestatin-treated U937 cells (PD20) and dominant-negative DN-hTERT-expressing U937 cells (PD25). Activation of p38 mitogen-activated protein (MAP) kinase and MKK3/6 was also found in telomestatin-treated U937 cells (PD20) and dominant-negative DN-hTERT-expressing U937 cells (PD25); however, activation of JNK and ASK1 was not detected in these cells. To examine the effect of p38 MAP kinase inhibition on growth properties and apoptosis in telomerase-inhibited cells, we cultured DN-hTERT-expressing U937 cells with or without SB203580. Dominant-negative-hTERT-expressing U937 cells stopped proliferation on PD25; however, a significant increase in growth rate was observed in the presence of SB203580. Treatment of SB203580 also reduced the induction of apoptosis in DN-hTERT-expressing U937 cells (PD25). These results suggest that p38 MAP kinase has a critical role for the induction of apoptosis in telomerase-inhibited leukemia cells. Further, we evaluated the effect of telomestatin on the growth of U937 cells in xenograft mouse model. Systemic intraperitoneal administration of telomestatin in U937 xenografts decreased tumor telomerase levels and reduced tumor volumes. Tumor tissue from telomestatin-treated animals exhibited marked apoptosis. None of the mice treated with telomestatin displayed any signs of toxicity. Taken together, these results lay the foundations for a program of drug development to achieve the dual aims of efficacy and selectivity in vivo.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Ame JC, Rolli V, Schreiber V, Niedergang C, Apiou P, Decker P et al. (1999). J Biol Chem 274: 17860–17868.

  • Bearss DJ, Hurley LH, Von Hoff DD . (2000). Oncogene 19: 6632–6641.

  • Blackburn E, Greider C (eds) (1995). Telomeres. Cold Spring Harbor Laboratory Press: New York.

    Google Scholar 

  • de Lange T . (2002). Oncogene 21: 532–540.

  • Gomez D, Aouali N, Renaud A, Douarre E, Shin-ya K, Tazi J et al. (2003). Cancer Res 63: 6149–6153.

  • Gomez D, Paterski R, Lemarteleur T, Shin-ya K, Mergny JL, Riou JF . (2004). J Biol Chem 279: 41487–41494.

  • Gowan SM, Heald R, Steavens MF, Kelland LR . (2001). Mol Pharmacol 60: 981–988.

  • Gowan SM, Harrion JR, Patterson L, Valenti M, Read MA, Neidle S et al. (2002). Mol Pharmacol 61: 1154–1162.

  • Iwasa H, Han J, Ishikawa F . (2003). Genes Cells 8: 131–144.

  • Izbicka E, Wheelhouse TR, Raymond E, Davidson KK, Lawrence RA et al. (1999). Cancer Res 59: 369–644.

  • Karlseder J, Smogorzewska A, de Lange T . (2002). Science 295: 2446–2449.

  • Kim MY, Vankayalapati H, Shin-ya K, Wierzba K, Hurley LH . (2002). J Am Chem Soc 124: 2098–2099.

  • Kim MY, Gleason-Guzman M, Izbicka E, Nishioka D, Hurley LH . (2003). Cancer Res 63: 3247–3256.

  • Mergeny JL, Helene C . (1998). Nat Med 4: 1366–1367.

  • Nakajima A, Tauchi T, Ohyashiki K . (2001). Leukemia 15: 989–990.

  • Nakajima A, Tauchi T, Sashida G, Sumi M, Abe K, Yamamoto K et al. (2003). Leukemia 17: 560–567.

  • Nebreda AR, Porras AR . (2000). Trend Biochem Sci 25: 257–260.

  • Ohyashiki JH, Sashida G, Tauchi T, Ohyashiki K . (2002). Oncogene 21: 680–687.

  • Olovnikov AM . (1973). J Ther Biol 41: 181–190.

  • Riou JF, Guittat L, Mailliet P, Laoui A, Renou E, Petitgenet O et al. (2002). Proc Natl Acad Sci USA 99: 2672–2677.

  • Schreiber VJ, Ame C, Dolle P, Schultz I, Rinaldi B, Fraulob V et al. (2002). J Biol Chem 277: 23028–23036.

  • Shammas MA, Reis RJ, Li C, Koley H, Hurley LH, Anderson KC et al. (2004). Clin Cancer Res 10: 770–776.

  • Sun D, Thompson B, Cathers BE, Salazar M, Kerwin SM, Trent JO et al. (1997). J Med Chem 40: 2113–2116.

  • Shin-ya K, Wierzba K, Matsuo K, Ohtani T, Yamada Y, Furihata K et al. (2001). J Am Chem Soc 123: 1262–1263.

  • Tauchi T, Feng GS, Shen R, Song HY, Donner D, Pawson T et al. (1994). J Biol Chem 269: 15381–15387.

  • Tauchi T, Nakajima A, Sashida G, Shimamoto T, Ohyashiki JH, Abe K et al. (2002). Clin Cancer Res 8: 3341–3347.

  • Tauchi T, Shin-ya K, Sashida G, Sumi M, Nakajima A, Shimamoto T et al. (2003). Oncogene 22: 5338–5374.

  • Wang XC, McGowan CH, Zhao M, He L, Downey JS, Fearns C et al. (2000). Mol Cell Biol 20: 4543–4552.

  • Watson JD . (1972). Nature 239: 197–201.

  • Wheelhouse RT, Sun D, Han H, Han FX, Hurley LH . (1998). J Am Chem Soc 120: 3261–3262.

  • White LK, Wright WE, Shay JW . (2001). Trends Biotech 19: 114–120.

  • Zahler AM, Williamson JR, Ceck TR, Prescott DM . (1991). Nature 350: 718–720.

Download references

Author information

Authors and Affiliations

  1. First Department of Internal Medicine, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan

    T Tauchi, G Sashida, M Sumi, S Okabe & K Ohyashiki

  2. Institute of Molecular and Cellular Biosciences, The University of Tokyo, Bunkyo-ku, Tokyo, Japan

    K Shin-ya

  3. Intractable Disease Research Center, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan

    J H Ohyashiki

Authors
  1. T Tauchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K Shin-ya
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G Sashida
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Sumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Okabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J H Ohyashiki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. K Ohyashiki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to T Tauchi or K Shin-ya.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tauchi, T., Shin-ya, K., Sashida, G. et al. Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: in vitro and in vivo studies in acute leukemia. Oncogene 25, 5719–5725 (2006). https://doi.org/10.1038/sj.onc.1209577

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1209577

Keywords

This article is cited by

Search

Advanced search

Quick links